Roth Capital Maintains Buy on Sarepta Therapeutics Inc as DMD-Sector Heating Up
In a research report released Sunday, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics Inc. (NASDAQ:SRPT) with a price target of $45, which implies an upside of 68.5% from current levels.
Chattopadhyay observed, “Sarepta is expected to complete its NDA filing by mid-15, which is potentially driven by a positive read from dystrophin re-scoring and corroborated by the fourth biopsy. Interestingly, competitors BioMarin and PTC Therapeutics are holding a joint “educational” symposium (June 22) where we anticipate the pivotal role of dystrophin is likely to be undermined, since neither drisapersen or Translarna have compelling mechanistic support of denovo dystrophin production.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of 34.2% and a 73.2% success rate. Chattopadhyay has a 49.6% average return when recommending SRPT, and is ranked #12 out of 3612 analysts.